Blog | BioInformant

The Pros and Cons of Stem Cell Research in 2026

October 2, 2025 By Cade Hildreth, Founder & President Leave a Comment

Interested to understand the importance of stem cell research and recent advancements within this field of study? Today, there are approximately 250 companies worldwide that are developing stem cell products for therapeutic use in humans to address a diverse range of chronic and acute conditions. There are also around astounding 500,000+ scientific publications about stem cells that have been published today in peer-reviewed journals.

In this article, we’ll explore the pros and cons of stem cell research. Let’s dive in.

In this article:

Pros of Stem Cell Research
Cons of Stem Cell Research

[Read more…]

Exploring Advanced Therapies in Diabetes Treatment: A Glimpse into the Future

October 1, 2025 By Cade Hildreth, Founder & President Leave a Comment

Diabetes is a chronic condition affecting millions globally, characterized by high blood sugar levels due to the body’s inability to produce or effectively use insulin. Traditional management strategies, including lifestyle modifications and medications, have been vital in controlling diabetes, but they often fall short of addressing the disease’s complexities and long-term complications. In recent years, advanced therapies have emerged, offering new hope for patients.

These therapies encompass innovations such as regenerative medicine, advanced insulin delivery systems, and gene editing technologies, each bringing us closer to more effective and personalized treatments. [Read more…]

MSCs as a Pivotal Tool for Cell Therapy, Gene Therapy, and Tissue Engineering

September 30, 2025 By Cade Hildreth, Founder & President Leave a Comment

MSCs have many fascinating properties, including strong immunomodulatory effects, the ability to repair damaged tissues, and the capacity in vitro to differentiate into other cells types. These traits, combined with their easy availability from different sources, has prompted researchers to look at MSCs as promising raw materials for use in cell therapy, gene therapy, and tissue engineering, the three pillars of regenerative medicine. The cumulative efforts of scientists, researchers and life science companies have resulted in the approval of 12 MSC-based cell therapies (several of which have been approved in multiple regions) and 19 MSC-based bone matrices. [Read more…]

The Emerging Role of Regenerative Treatments in Diabetic Wound Care

September 30, 2025 By Cade Hildreth, Founder & President Leave a Comment

Diabetes is a condition that affects millions worldwide, and one of its most challenging complications is the development of chronic wounds, including skin wounds and ulcers. These persistent wounds are not only painful and debilitating but also pose significant risks for infection and amputation. Traditional treatments often fall short, leading to the exploration of advanced regenerative therapies, including stem cells and exosomes, which have the potential to transform the management of these difficult conditions.

Companies are making significant strides in this field, and clinical trials are underway to test the effectiveness of these innovative approaches. [Read more…]

uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells

September 30, 2025 By BioInformant Team Leave a Comment

GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed and proven to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cell (iPSC). [Read more…]